In a publication last week, researchers described efforts to improve in silico methods for investigating the pathogenicity of missense BRCA1/2 variants of unknown significance.

Public health microbiologists are forging ahead with WGS, even as others caution that it may not yet be ready for such a role, said speakers at ASM Microbe 2018.

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

After the arrest of the Golden State Killer, ethicists say the government must delineate acceptable limits for future uses of public DNA databases.

With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.

In silico molecular biology tools, electronic lab notebooks, and systems for registration,
sample management, workflow management, and request management form the
foundation of informatics for biologics R&D.

When building out their informatics, most R&D organizations evaluate these solutions
independently, by checking off a list of required features. This is a good starting point, but
what are you missing by not evaluating the platform capabilities of these solutions?

The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.

Highly predictive patient-derived xenograft (PDX) models can predict clinical efficacy for oncology drug candidates better than traditional cell line-derived preclinical models. This white paper describes how PDX models can be used in Mouse Clinical Trials, upending the traditional paradigm in animal studies and providing a better perspective of patient-to-patient heterogeneity.